Rapid Subcutaneous Drug Delivery Device
Background
The technology has been developed within a London NHS Trust. NHSIL have commissioned initial fluid dynamic studies leading to the design of a new rapid subcutaneous infusion device system.
Solution
This new concept is designed to significantly reduce the time for infusion as the patient can quickly self administer the drug manually without the need for a pump and without any swelling. The device is an entirely subcutaneous fenestrated catheter attached to an injection port with an easily accessible septum for administration of IG through the skin into the port. The injection port is a small port implanted under the skin that is capped with a silicone plug that provides a large target for needles and can be injected hundreds of times before replacement is required.
Key Features and Benefits:
- Significantly reduces the infusion time from >90mins for current infusion methods
- Reduces the amount of discomfort for the patient
- Removes the requirement for SCIG pumps and associated visits to hospital
- Potential savings for hospitals on associated costs and equipment
- Increasing use of SCIG within the health care system
- Potential application for delivery of other drugs administered subcutaneously
Market Potential
There are currently over 35,000 people receiving IG therapy in the US and this device is estimated to save >£10,000 per patient over 5 years.
This product is currently available to license from NHSIL.
